10-K: Cardiff Oncology Faces Going Concern Doubt Amid Clinical Progress

Cardiff Oncology's latest 10-K reveals promising clinical trial data for onvansertib in mCRC and mTNBC, but highlights significant financial challenges and a going concern warning.

Summary

• Cardiff Oncology is a clinical-stage biotechnology company focused on PLK1 inhibition, with its lead drug candidate, onvansertib, being developed for various cancers.
• Onvansertib is an oral, highly selective PLK1 inhibitor with a 24-hour half-life, demonstrating synergistic effects in combination with standard-of-care (SoC) therapeutics in preclinical studies.
• The CRDF-004 Phase 2 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC) showed a confirmed Objective Response Rate (ORR) of 72.2% for the Onv 30 mg + FOLFIRI/bevacizumab arm, compared to 43.2% for SoC, with a p-value of 0.051.
• Median Progression-Free Survival (PFS) in the CRDF-004 trial was not reached for the onvansertib arms, versus 10.97 months for SoC, with a p-value of 0.048.
• Onvansertib in combination with paclitaxel demonstrated a 40% objective response rate in a Phase 1b trial for metastatic triple-negative breast cancer (mTNBC).
• Preliminary efficacy was observed in approximately 40% of patients in a Phase 1 trial of onvansertib monotherapy for Chronic Myelomonocytic Leukemia (CMML).
• The company reported a net loss of $45.9 million for the fiscal year ended December 31, 2025, and an accumulated deficit of $430.0 million.
• Cash, cash equivalents, and short-term investments totaled $58.3 million as of December 31, 2025, which is projected to fund operations only into the first quarter of 2027.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• Nerviano Medical Sciences has alleged a material breach of the license agreement for onvansertib patents, which could lead to the termination of critical license rights.
• Mani Mohindru was appointed interim Chief Executive Officer, and Brigitte Lindsay was promoted to Chief Accounting Officer, effective January 27, 2026, following the departure of Mark Erlander (CEO) and James Levine (CFO).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a high-risk, high-reward scenario. While clinical data for onvansertib shows promise, particularly in mCRC, the significant going concern warning and the Nerviano licensing dispute create substantial uncertainty regarding the company's long-term viability and ability to capitalize on its pipeline.

Positives

• The CRDF-004 Phase 2 trial in first-line RAS-mutated mCRC demonstrated a strong confirmed Objective Response Rate (ORR) of 72.2% for the Onv 30 mg + FOLFIRI/bevacizumab arm, significantly outperforming the 43.2% for standard of care (p-value = 0.051).
• Progression-Free Survival (PFS) data from CRDF-004 showed a favorable trend, with median PFS not reached in the onvansertib arms compared to 10.97 months for the standard of care arm (p-value = 0.048).
• Onvansertib in combination with chemo/bevacizumab was well-tolerated in CRDF-004, with no major or unexpected toxicities observed.
• The Phase 1b mTNBC trial of onvansertib in combination with paclitaxel showed a promising 40% objective response rate by RECIST 1.1 at the recommended Phase 2 dose (RP2D) of 18mg/m2 (n=10).
• Onvansertib monotherapy demonstrated preliminary efficacy in approximately 40% of patients in the Phase 1 dose-escalation trial for CMML.
• The company has a strategic partnership with Pfizer Ignite for the CRDF-004 trial, leveraging Pfizer's significant R&D capabilities and expertise.
• The FDA agreed at a Type C meeting in June 2023 that a seamless Phase 2/3 trial design with an interim ORR endpoint is acceptable for accelerated approval, with PFS and lack of detriment on overall survival for full approval.
• The company holds an extensive intellectual property portfolio, including 51 issued patents and 65 pending applications, with some patents extending protection until 2045.

Negatives

• The company has an accumulated deficit of $430.0 million as of December 31, 2025, and has incurred recurring net losses from operations ($45.9 million in 2025 and $45.5 million in 2024).
• Cash, cash equivalents, and short-term investments of $58.3 million as of December 31, 2025, are only sufficient to fund operations into the first quarter of 2027, leading to a substantial doubt about the company's ability to continue as a going concern.
• Working capital significantly decreased from $81.6 million in 2024 to $43.7 million in 2025.
• Nerviano Medical Sciences has sent a notice alleging a material breach of the license agreement for onvansertib patents, which could result in the termination of critical license rights and a material adverse effect on the business.
• The company has limited internal drug discovery capabilities and relies on in-licensing or acquisitions for pipeline expansion.
• Dependence on third-party manufacturers and contract research organizations (CROs) introduces risks related to production, quality control, and compliance with stringent regulations.

Risks

• The company is a clinical-stage entity and may never earn a profit, having incurred losses since its formation and expecting substantial net losses for the foreseeable future.
• Substantial additional capital is required to develop and commercialize onvansertib; failure to obtain funding when needed may force delays, reductions, or elimination of product development programs.
• Management has concluded that there exists a substantial doubt about the company's ability to continue as a going concern, which may hinder future financing.
• Onvansertib is in early-mid stages of clinical development, and its commercial viability is uncertain, subject to current and future preclinical studies, clinical trials, and regulatory approvals.
• Unfavorable or delayed results from preclinical studies or clinical trials could delay or preclude further development or commercialization of onvansertib.
• Reliance on third-party vendors to conduct preclinical studies or clinical trials poses risks of delays, termination, or increased expenses if they fail to perform or comply with strict regulations.
• Limited capacity for recruiting and managing clinical trials could impair the timing to initiate or complete trials.
• The company and its collaborators must comply with extensive government regulations to advance product candidates and obtain marketing approval, which is a lengthy, time-consuming, and unpredictable process.
• If the company materially breaches or defaults under the Nerviano Licensing Agreement, Nerviano will have the right to terminate the agreement, leading to the loss of critical license rights and a material adverse effect on the business.
• Security threats to information technology infrastructure and/or physical buildings could expose the company to liability and damage its reputation and business.
• Healthcare reform measures, including the ACA and IRA, could adversely affect the business by impacting product pricing, reimbursement, and market access.
• Inability to effectively protect intellectual property could impair competitive advantage, and third-party patents or other intellectual property rights may block or compete with potential products.
• The common stock price may be volatile and could fluctuate widely, resulting in substantial losses for investors.
• The company's ability to use its net operating loss carryforwards and certain other tax attributes is limited by Sections 382 and 383 of the Internal Revenue Code.
• Business disruptions, including natural disasters, pandemics (like COVID-19), and geopolitical risks, could materially adversely impact operations, supply chain, and financial condition.

Future Outlook

The company plans to initiate CRDF-005, a Phase 3 randomized trial with registrational intent, contingent upon the results of CRDF-004. The FDA has agreed to a seamless Phase 2/3 trial design with Objective Response Rate (ORR) as an interim endpoint for accelerated approval, and Progression-Free Survival (PFS) and lack of detriment on overall survival for full approval. The company expects to incur substantial net losses for the foreseeable future and will require additional capital to further advance its clinical trial programs and support other operations, as current capital resources are only sufficient into the first quarter of 2027. The timing and amount of future revenues from drug sales are uncertain.

Management Comments

• "Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ('SoC') therapeutics."
• "We believe the attributes of onvansertib described below, as well as early clinical evidence of favorable safety and efficacy, with expected on-target, manageable and tolerable side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers."
• "We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law."
• "Management has performed an analysis and concluded that there exists a substantial doubt about our ability to continue as a going concern."
• "We intend to vigorously defend our rights under the license agreement [with Nerviano]."

Industry Context

StockSavvy.ai notes that Cardiff Oncology operates in a highly competitive oncology market, with its lead candidate onvansertib, a PLK1 inhibitor, facing competition from other approved and investigational therapies. The company's strategy of combining onvansertib with standard-of-care therapeutics and focusing on biomarker-driven patient selection aligns with broader industry trends towards precision medicine and combination therapies to overcome resistance. The partnership with Pfizer Ignite could provide a competitive advantage by leveraging Pfizer's R&D capabilities, but the financial challenges and reliance on external funding are common for clinical-stage biotechs.

Comparison to Industry Standards

• Onvansertib is highlighted as the only oral PLK1 inhibitor in active clinical development that delivers highly selective PLK1 inhibition, differentiating it from prior pan-PLK inhibitors.
• Volasertib, a pan-PLK inhibitor developed by Boehringer Ingelheim, failed its Phase 3 AML trial due to an unfavorable safety profile, which Cardiff Oncology attributes to its less selective PLK inhibition compared to onvansertib.
• Onvansertib's 24-hour half-life is presented as favorable compared to volasertib's 135 hours, offering more flexible dosing.
• In RAS-mutated mCRC, competitors include BMS's KRAZATI (adagrasib), which has accelerated FDA approval for previously treated KRAS G12C-mutated mCRC, as well as ongoing clinical trials by Amgen, Pfizer, and Summit Therapeutics evaluating targeted and immuno-oncology approaches.
• Cardiff's CRDF-004 trial's 72.2% ORR in the 30mg arm for first-line RAS-mutated mCRC compares favorably to typical ORRs for standard of care in this difficult-to-treat population, suggesting a potential improvement over existing options, though direct head-to-head comparisons with specific competitor drugs are not detailed in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• A putative stockholder class action, Vrana v. James O. Armitage et al., filed on May 13, 2024, was mooted on June 20, 2024, after stockholders approved certain proposals. The company agreed to pay $400,000 in attorneys' fees and expenses to the plaintiffs' counsel in September 2024.
• On February 18, 2026, Nerviano Medical Sciences sent a written notice alleging a material breach of the license agreement regarding alleged joint ownership of certain U.S. patents (12.144.813 and 12.263.173) and the filing of a joint invention continuation patent application. The company believes it has meritorious defenses and intends to vigorously defend its rights; if unsuccessful, Nerviano may terminate the license, which would have a material adverse effect on the business.

Related Party Transactions

• In November 2021, Pfizer Inc. purchased 2.4 million shares of common stock for approximately $15.0 million as part of the Pfizer Breakthrough Growth Initiative. Nicholas Choong, MD, Pfizer's designee, is on the company's Scientific Advisory Board. Pfizer Ignite is responsible for the clinical activities of the CRDF-004 trial, with Cardiff Oncology maintaining financial responsibility and full economic ownership of onvansertib.

Stakeholder Impact

• Shareholders face potential significant dilution if additional equity financing is pursued and risk substantial losses due to stock price volatility and the going concern uncertainty. The Nerviano licensing dispute also poses a risk to the value of their investment.
• Employees are impacted by recent management changes, including the appointment of an interim CEO and a new Chief Accounting Officer. The company's ability to attract and retain qualified personnel is critical for its success.
• Patients and the medical community could benefit from the continued development of onvansertib as a potential new treatment option for various cancers, but delays or failures in development would limit access to these therapies.
• Creditors face increased risk due to the company's recurring net losses, negative operating cash flows, and the explicit going concern warning.
• Suppliers and contractors, particularly third-party manufacturers and CROs, are critical to the company's operations, and their performance and financial stability directly impact the company's ability to execute its development programs.

Next Steps

• Initiate CRDF-005, a Phase 3 randomized trial with registrational intent, contingent upon the results of CRDF-004.
• Finalize the complete Phase 3 trial design after discussion with the FDA upon sharing the full CRDF-004 trial results.
• Continue monitoring patients in the CRDF-004 study for efficacy and safety.
• Continue enrollment for the investigator-initiated mPDAC Phase 1b/2 trial.
• Continue enrollment for the Phase 2 SCLC trial (Stage 2 if 2 or more Stage 1 patients achieve an objective response).
• Continue dose expansion and recruiting at the 12 mg/m2 dose for the CMML Phase 1 trial.
• Respond to Nerviano's notice of alleged material breach within the applicable cure period and vigorously defend rights under the license agreement.
• Seek additional equity or debt financing, obtain government grants, or reduce expenditures to address the going concern uncertainty.

Key Dates

Recommendation

Cardiff Oncology presents a mixed bag of strong clinical trial results for onvansertib in mCRC and mTNBC, indicating potential therapeutic value. However, the company's severe liquidity issues, explicit going concern warning, and the material breach allegation from Nerviano Medical Sciences regarding its core intellectual property create immense financial and operational uncertainty. A seasoned investor would likely hold existing positions to monitor the resolution of these critical financial and legal challenges, as the upside from clinical success is currently overshadowed by significant existential risks. New investment would be highly speculative until these fundamental issues are addressed.

Keywords

Oncology, Biotechnology, PLK1 inhibitor, Onvansertib, RAS-mutated mCRC, Metastatic Colorectal Cancer, mPDAC, Pancreatic Cancer, SCLC, Small Cell Lung Cancer, mTNBC, Triple Negative Breast Cancer, CMML, Chronic Myelomonocytic Leukemia, Clinical Trials, Phase 2, Phase 3, FDA Approval, Drug Development, Going Concern, Intellectual Property, Licensing Agreement, Pfizer Ignite, SEC Filing, 10-K